[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit ::
Main Menu
Journal Information::
Articles Archive::
Guide for Authors::
For Reviewers::
Ethical Statements::
Site Facilities::
Contact us::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Copyright Policies




Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

:: Volume 10, Issue 2 (Spring 2022) ::
Shefaye Khatam 2022, 10(2): 1-9 Back to browse issues page
Neuroprotective Effects of Silymarin-Loaded Chitosan Nanoparticles on Ketamine-Induced Cognitive Disorders and Oxidative Damages in Mice Hippocampus
Akbar Hajizadeh moghaddam * , Reza Barari , Sedigheh Khanjani jelodar , Vahid Hasantabar
Department of Physiology, Department of Animal Sciences, Faculty of Basic Sciences, Mazandaran University, Babolsar, Iran , a.hajizadeh@umz.ac.ir
Abstract:   (1315 Views)
Introduction: Oxidative stress plays a key role in the pathophysiology of schizophrenia, a debilitating mental illness. Silymarin (SM) is a flavonoid with antioxidant properties found in Silybum marianum. However, the bioavailability of SM is rather low due to poor water solubility. The purpose of this study was to investigate the effect of neuroprotective of silymarin-loaded chitosan nanoparticles (SM-CS-NPs) on ketamine-induced cognitive disorders and hippocampal oxidative damages. Materials and Methods: In this study, 35 male mice were divided into five groups; control and four ketamin groups treated with saline, aripiprazole, SM, and SM-CS-NPs at doses of 20 mg/kg/30 days, respectively. In the experimental groups, animals received ketamine (20 mg/kg/day) from the 16th to the 30th day intraperitoneally. Cognitive deficits were evaluated employing a novel object recognition test (NORT). Furthermore, various oxidative stress markers in the hippocampal area were assessed. Results: Our results revealed that ketamine significantly reduced the discrimination index and catalase, superoxide dismutase, and glutathione reductase enzyme activity compared with the control group. Moreover, treatment with SM and SM-CS-NPs reduced cognitive impairments, increased the activity of the antioxidant enzymes catalase, superoxide dismutase as well as glutathione reductase, and reduced malondialdehyde levels in the treatment groups. Conclusion: SM-CS-NPs may improve SM bioavailability and exert stronger neuroprotective effects against ketamine-induced cognitive deficits and hippocampal oxidative damages.
Keywords: Ketamine, Silymarin, Schizophrenia
Full-Text [PDF 881 kb]   (754 Downloads)    
Type of Study: Research --- Open Access, CC-BY-NC | Subject: Neurophysiology
1. Alavian F, Alavian K, Ghiasvand S, Rezaeian L. Protective Effects of Cherry Extract on Malondialdehyde Levels, Catalase Activity, and Edema Induced by Middle Cerebral Artery Occlusion in a Rat Stroke Model. The Neuroscience Journal of Shefaye Khatam. 2020; 8(3): 1-9. [DOI:10.29252/shefa.8.3.1]
2. Ahmadi M, Banazadeh Dardashti M, Karimzadeh F. The anti-aggressive effect of music therapy in an animal model of schizophrenia. The Neuroscience Journal of Shefaye Khatam. 2014; 2(1):51-5. [DOI:10.18869/acadpub.shefa.2.1.51]
3. MacDonald AW, Schulz SC. What we know: findings that every theory of schizophrenia should explain. Schizophrenia bulletin. 2009; 35(3): 493-508. [DOI:10.1093/schbul/sbp017]
4. Hintze B, Borkowska A. Intensity of negative symptoms, working memory and executive functions disturbances in schizophrenic patients in partial remission period. Psychiatria Polska. 2011; 45(4): 457-67.
5. Ben-Azu B, Aderibigbe AO, Eneni A-EO, Ajayi AM, Umukoro S, Iwalewa EO. Morin attenuates neurochemical changes and increased oxidative/nitrergic stress in brains of mice exposed to ketamine: prevention and reversal of schizophrenia-like symptoms. Neurochemical Research. 2018; 43(9): 1745-55. [DOI:10.1007/s11064-018-2590-z]
6. Xu K, Lipsky RH. Repeated ketamine administration alters N-methyl-D-aspartic acid receptor subunit gene expression: implication of genetic vulnerability for ketamine abuse and ketamine psychosis in humans. Experimental Biology and Medicine. 2015; 240(2): 145-55. [DOI:10.1177/1535370214549531]
7. Leri M, Scuto M, Ontario ML, Calabrese V, Calabrese EJ, Bucciantini M, et al. Healthy effects of plant polyphenols: molecular mechanisms. International journal of molecular sciences. 2020; 21(4): 1250. [DOI:10.3390/ijms21041250]
8. Maleki SJ, Crespo JF, Cabanillas B. Anti-inflammatory effects of flavonoids. Food Chemistry. 2019; 299: 125124. [DOI:10.1016/j.foodchem.2019.125124]
9. Wang MJ, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, et al. Silymarin protects dopaminergic neurons against lipopolysaccharide‐induced neurotoxicity by inhibiting microglia activation. European Journal of Neuroscience. 2002; 16(11): 2103-12. [DOI:10.1046/j.1460-9568.2002.02290.x]
10. Ghosh A, Ghosh T, Jain S. Silymarin-a review on the pharmacodynamics and bioavailability enhancement approaches. Journal of Pharmaceutical Science and Technology. 2010; 2(10): 348-55.
11. Afjeh Dana E, Marivani M, Mehravi B, Karimzadeh F, Ashtari K. Development of Nanoparticles for Drug Delivery to the Brain. The Neuroscience Journal of Shefaye Khatam. 2017; 5(2): 76-87. [DOI:10.18869/acadpub.shefa.5.2.76]
12. Ali A, Ahmed S. A review on chitosan and its nanocomposites in drug delivery. International journal of biological macromolecules. 2018; 109: 273-86. [DOI:10.1016/j.ijbiomac.2017.12.078]
13. Moghaddam AH, Maboudi K, Bavaghar B, Sangdehi SRM, Zare M. Neuroprotective effects of curcumin-loaded nanophytosome on ketamine-induced schizophrenia-like behaviors and oxidative damage in male mice. Neuroscience Letters. 2021; 765: 136249. [DOI:10.1016/j.neulet.2021.136249]
14. Moghaddam AH, Sangdehi SRM, Ranjbar M, Hasantabar V. Preventive effect of silymarin-loaded chitosan nanoparticles against global cerebral ischemia/reperfusion injury in rats. European Journal of Pharmacology. 2020; 877: 173066. [DOI:10.1016/j.ejphar.2020.173066]
15. Antunes M, Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cognitive processing. 2012; 13(2): 93-110. [DOI:10.1007/s10339-011-0430-z]
16. Olson BJ, Markwell J. Assays for determination of protein concentration. Current Protocols in Pharmacology. 2007; 38(1): A. 3A. 1-A. 3A. 29. [DOI:10.1002/0471141755.pha03as38]
17. Genet S, Kale RK, Baquer NZ. Alterations in antioxidant enzymes and oxidative damage in experimental diabetic rat tissues: effect of vanadate and fenugreek (Trigonella foenum graecum). Molecular and cellular biochemistry. 2002; 236(1): 7-12. [DOI:10.1023/A:1016103131408]
18. Romero FJ, Romá J, Bosch-Morell F, Romero B, Segura-Aguilar J, Llombart-Bosch A, et al. Reduction of brain antioxidant defense upon treatment with butylated hydroxyanisole (BHA) and Sudan III in Syrian golden hamster. Neurochemical research. 2000; 25(3): 389-93. [DOI:10.1023/A:1007549222553]
19. Kim MS, Lee JI, Lee WY, Kim SE. Neuroprotective effect of Ginkgo biloba L. extract in a rat model of Parkinson's disease. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives. 2004; 18(8): 663-6. [DOI:10.1002/ptr.1486]
20. Demir M, Amanvermez R, Polat AK, Karabıçak I, Cınar H, Kesicioğlu T, et al. The effect of silymarin on mesenteric ischemia-reperfusion injury. Medical Principles and Practice. 2014; 23(2): 140-4. [DOI:10.1159/000356860]
21. Urban-Kowalczyk M, Pigońska J, Śmigielski J. Pain perception in schizophrenia: influence of neuropeptides, cognitive disorders, and negative symptoms. Neuropsychiatric disease and treatment. 2015; 11: 2023. [DOI:10.2147/NDT.S87666]
22. Hauser MJ, Isbrandt D, Roeper J. Disturbances of novel object exploration and recognition in a chronic ketamine mouse model of schizophrenia. Behavioural brain research. 2017; 332: 316-26. [DOI:10.1016/j.bbr.2017.06.013]
23. Białoń M, Żarnowska M, Antkiewicz-Michaluk L, Wąsik A. Pro-cognitive effect of 1MeTIQ on recognition memory in the ketamine model of schizophrenia in rats: the behavioural and neurochemical effects. Psychopharmacology. 2020; 237(6): 1577-93. [DOI:10.1007/s00213-020-05484-1]
24. Kawaura K, Koike H, Kinoshita K, Kambe D, Kaku A, Karasawa J-i, et al. Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats. Behavioural brain research. 2015; 278: 186-92. [DOI:10.1016/j.bbr.2014.09.046]
25. Coronel‐Oliveros CM, Pacheco‐Calderón R. Prenatal exposure to ketamine in rats: Implications on animal models of schizophrenia. Developmental psychobiology. 2018; 60(1): 30-42. [DOI:10.1002/dev.21586]
26. Fan N, Luo Y, Xu K, Zhang M, Ke X, Huang X, et al. Relationship of serum levels of TNF-α, IL-6 and IL-18 and schizophrenia-like symptoms in chronic ketamine abusers. Schizophrenia research. 2015; 169(1-3): 10-5. [DOI:10.1016/j.schres.2015.11.006]
27. Pradhan S, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian journal of medical research. 2006; 124(5): 491.
28. Haddadi R, Shahidi Z, Eyvari-Brooshghalan S. Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms. Phytomedicine. 2020; 79: 153320. [DOI:10.1016/j.phymed.2020.153320]
29. Younis N, Shaheen MA, Abdallah MH. Silymarin-loaded Eudragit® RS100 nanoparticles improved the ability of silymarin to resolve hepatic fibrosis in bile duct ligated rats. Biomedicine & Pharmacotherapy. 2016; 81: 93-103. [DOI:10.1016/j.biopha.2016.03.042]
30. Hajizadeh Moghaddam A. The protective effect of quince (Cydonia oblonga Miller) leaf extract on locomotor activity and anxiety-like behaviors in a ketamine model of schizophrenia. Journal of Arak University of Medical Sciences. 2016; 19(5): 31-41.
31. Kuen CY, Fakurazi S, Othman SS, Masarudin MJ. Increased loading, efficacy and sustained release of silibinin, a poorly soluble drug using hydrophobically-modified chitosan nanoparticles for enhanced delivery of anticancer drug delivery systems. Nanomaterials. 2017; 7(11): 379. [DOI:10.3390/nano7110379]

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

hajizadeh moghaddam A, barari R, khanjani jelodar S, hasantabar V. Neuroprotective Effects of Silymarin-Loaded Chitosan Nanoparticles on Ketamine-Induced Cognitive Disorders and Oxidative Damages in Mice Hippocampus. Shefaye Khatam 2022; 10 (2) :1-9
URL: http://shefayekhatam.ir/article-1-2292-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 10, Issue 2 (Spring 2022) Back to browse issues page
مجله علوم اعصاب شفای خاتم The Neuroscience Journal of Shefaye Khatam
Persian site map - English site map - Created in 0.06 seconds with 45 queries by YEKTAWEB 4652